A detailed history of Raymond James & Associates transactions in Illumina, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 441,182 shares of ILMN stock, worth $59.6 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares
441,182
Previous 316,109 39.57%
Holding current value
$59.6 Million
Previous $33 Million 74.36%
% of portfolio
0.04%
Previous 0.02%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$105.28 - $135.9 $13.2 Million - $17 Million
125,073 Added 39.57%
441,182 $57.5 Million
Q2 2024

Jul 19, 2024

SELL
$101.05 - $133.57 $5.45 Million - $7.2 Million
-53,940 Reduced 14.58%
316,109 $33 Million
Q1 2024

Apr 22, 2024

BUY
$127.73 - $147.2 $2.15 Million - $2.48 Million
16,831 Added 4.77%
370,049 $50.8 Million
Q4 2023

Jan 16, 2024

SELL
$92.79 - $142.53 $2.6 Million - $3.99 Million
-28,015 Reduced 7.35%
353,218 $49.2 Million
Q3 2023

Oct 24, 2023

BUY
$128.91 - $192.44 $7.92 Million - $11.8 Million
61,444 Added 19.21%
381,233 $52.3 Million
Q2 2023

Jul 25, 2023

BUY
$183.43 - $232.67 $4.43 Million - $5.62 Million
24,140 Added 8.17%
319,789 $60 Million
Q1 2023

Apr 14, 2023

BUY
$193.75 - $232.55 $12.3 Million - $14.7 Million
63,299 Added 27.24%
295,649 $68.8 Million
Q4 2022

Feb 08, 2023

BUY
$187.24 - $242.74 $1.99 Million - $2.58 Million
10,620 Added 4.79%
232,350 $47 Million
Q3 2022

Oct 25, 2022

BUY
$177.23 - $227.44 $61,321 - $78,694
346 Added 0.16%
221,730 $42.3 Million
Q2 2022

Aug 12, 2022

BUY
$181.58 - $368.0 $593,221 - $1.2 Million
3,267 Added 1.5%
221,384 $40.8 Million
Q1 2022

May 11, 2022

SELL
$303.87 - $423.8 $138,564 - $193,252
-456 Reduced 0.21%
218,117 $76.2 Million
Q4 2021

Feb 08, 2022

BUY
$347.28 - $421.83 $4.26 Million - $5.18 Million
12,280 Added 5.95%
218,573 $83.2 Million
Q3 2021

Nov 02, 2021

BUY
$405.61 - $524.84 $3.23 Million - $4.18 Million
7,973 Added 4.02%
206,293 $83.7 Million
Q2 2021

Aug 11, 2021

SELL
$372.84 - $481.5 $6.49 Million - $8.39 Million
-17,418 Reduced 8.07%
198,320 $93.8 Million
Q1 2021

May 14, 2021

BUY
$361.28 - $504.76 $2.55 Million - $3.57 Million
7,065 Added 3.39%
215,738 $82.9 Million
Q4 2020

Feb 12, 2021

BUY
$292.7 - $370.96 $13.3 Million - $16.8 Million
45,414 Added 27.82%
208,673 $77.2 Million
Q3 2020

Nov 04, 2020

BUY
$268.51 - $400.74 $686,043 - $1.02 Million
2,555 Added 1.59%
163,259 $50.5 Million
Q2 2020

Jul 28, 2020

BUY
$256.46 - $373.01 $10 Million - $14.6 Million
39,011 Added 32.06%
160,704 $59.5 Million
Q1 2020

Apr 21, 2020

SELL
$209.2 - $335.53 $213,593 - $342,576
-1,021 Reduced 0.83%
121,693 $33.2 Million
Q4 2019

Feb 12, 2020

BUY
$288.29 - $335.49 $240,145 - $279,463
833 Added 0.68%
122,714 $40.7 Million
Q3 2019

Nov 07, 2019

SELL
$266.84 - $378.23 $6.08 Million - $8.62 Million
-22,789 Reduced 15.75%
121,881 $37.1 Million
Q2 2019

Aug 06, 2019

BUY
$300.59 - $368.15 $4.67 Million - $5.72 Million
15,524 Added 12.02%
144,670 $53.3 Million
Q1 2019

May 06, 2019

BUY
$272.57 - $321.18 $10.7 Million - $12.6 Million
39,356 Added 43.83%
129,146 $40.1 Million
Q4 2018

Feb 11, 2019

BUY
$272.46 - $366.54 $3.1 Million - $4.17 Million
11,365 Added 14.49%
89,790 $26.9 Million
Q3 2018

Nov 14, 2018

BUY
$279.04 - $367.06 $7.41 Million - $9.75 Million
26,568 Added 51.23%
78,425 $28.8 Million
Q2 2018

Aug 14, 2018

BUY
$228.17 - $292.07 $4.1 Million - $5.25 Million
17,967 Added 53.02%
51,857 $14.5 Million
Q1 2018

May 14, 2018

BUY
$209.54 - $253.91 $911,918 - $1.11 Million
4,352 Added 14.73%
33,890 $8.01 Million
Q4 2017

Feb 14, 2018

BUY
$202.23 - $230.03 $458,253 - $521,247
2,266 Added 8.31%
29,538 $6.45 Million
Q3 2017

Nov 13, 2017

BUY
$172.3 - $213.93 $112,511 - $139,696
653 Added 2.45%
27,272 $5.43 Million
Q2 2017

Aug 14, 2017

BUY
N/A
26,619
26,619 $4.62 Million

Others Institutions Holding ILMN

About ILLUMINA, INC.


  • Ticker ILMN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 157,300,000
  • Market Cap $21.2B
  • Description
  • Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments....
More about ILMN
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.